USTR Initiates Section 301 Investigation Into Germany's Pharmaceutical Pricing Practices
USTR has initiated a Section 301 investigation targeting Germany's persistent underpayment for innovative pharmaceutical products, with a Federal Register notice formally opening the proceeding and inviting public comment. While no tariff actions have been imposed yet, this investigation could ultimately result in additional duties on imports of German-origin goods if USTR determines the practices are actionable.
Section 301 investigations historically lead to tariff actions, and importers sourcing goods from Germany — particularly in pharmaceuticals or related sectors — should begin tracking this proceeding and considering supply-chain contingencies. We recommend participating in the public comment process if your business could be affected by potential retaliatory measures.
AI-assisted summary with JFS CHB broker commentary, for awareness only — always verify against the official CBP/USITC/Federal Register notice before acting.